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ABSTRACT 
Background: Proprotein convertase subtilisin/kexin type 9 (PCSK9) binds low-density 
lipoprotein receptor (LDLR) preventing its recycling. PCSK9 is a risk predictor and a 
biotarget in atherosclerosis progression.  
Objectives: We determined whether the PCSK9-LDLR axis could predict risk in 
patients with heart failure (HF). 
Patients and Methods: The BIOSTAT-CHF is a multicenter, multinational, prospective, 
observational study that included patients with worsening HF signs and/or symptoms. 
The primary endpoints were all-cause mortality and the composite of mortality or 
unscheduled hospitalizations for HF. We implemented Cox proportional hazard 
regression to determine the simultaneously-adjusted effect of PCSK9 and LDLR on 
both outcomes, when added to the previously validated BIOSTAT risk scores.  
Results: This study included 2174 patients (mean age 68 ± 12 years; 53.2% had a 
history of ischemic heart disease). Median (IQR) PCSK9 and LDLR levels were 
1.81U/mL (1.45-2.18) and 2.98 U/mL (2.45-3.53), respectively. During follow-up, 569 
deaths (26.2%) and 896 (41.2%) composite endpoints were ascertained. A multivariable 
analysis, which included BIOSTAT risk scores, LDLR, and statin treatment as 
covariates, revealed a positive linear association between PCSK9 levels and the risk of 
mortality (HR=1.24; 95%CI 1.04-1.49; p=0.020) and the composite endpoint (HR=1.21; 
95%CI 1.05-1.40; p=0.010). A similar analysis for LDLR revealed a negative 
association with mortality (HR=0.86; 95%CI 0.76-0.98; p=0.025) and the composite 
endpoint (HR=0.92; 95%CI 0.83-1.01; p=0.087). Including PCSK9 and LDLR 
improved risk score performance. 
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Conclusions: The PCSK9-LDLR axis was associated with outcomes in patients with 
HF. Future studies must assess whether PCSK9 inhibition will result in better outcomes 
in HF. 
 
Keywords: Proprotein convertase subtilisin/kexin type 9 (PCSK9), low-density 
lipoprotein receptor (LDLR), heart failure.  
 
CONDENSED ABSTRACT 
Proprotein convertase subtilisin/kexin type 9 (PCSK9) binds low-density lipoprotein 
receptor (LDLR) preventing its recycling. We determined whether the PCSK9-LDLR 
axis could predict risk in patients with heart failure (HF) in the BIOSTAT-CHF study. 
A multivariable analysis, which included BIOSTAT risk scores, LDLR, and statin 
treatment as covariates, revealed a positive linear association between PCSK9 levels 
and the risk of mortality and the composite endpoint. A similar analysis for LDLR 
revealed a negative association with mortality and the composite endpoint. Future 
studies must assess whether PCSK9 inhibition will result in better outcomes in HF. 
 
ABBREVIATIONS 
HF - Heart failure 
PCSK-9- Proprotein convertase subtilisin/kexin type 9  
LDLR- low-density lipoprotein receptor 
BIOSTAT-CHF- BIOlogy Study to TAilored Treatment in Chronic Heart Failure 
LVEF- Left ventricular ejection fraction  
ACE- Angiotensin-converting enzyme 
PEA- Proximity Extension Assay technology 
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INTRODUCTION 
Major advances in heart failure (HF) management have been achieved over the last 
three decades by targeting two main pathways activated in HF, namely the renin-
angiotensin-aldosterone system and the sympathetic nervous system (1-5). 
Nevertheless, HF remains a syndrome with high morbidity and mortality, poor quality 
of life, and high health-care costs (6).  
Targeting alternative pathways that participate in the HF syndrome seem the 
next logical approach. One such pathway is atherosclerosis progression; however, the 
administration of statins in HF has led to debatable results. Indeed, the two major 
randomized trials that studied the effect of statin treatment in patients with chronic HF 
did not demonstrate sufficient evidence of benefit (7,8). However, at least in CORONA 
the secondary endpoint of heart failure hospitalization was significantly reduced by 
rosuvastatin (7). Also, some reports on real-life data have shown a positive association 
between statins and outcomes (9).  
A new biotarget for treating atherosclerosis progression is proprotein convertase 
subtilisin/kexin type 9 (PCSK9)(10,11). Secreted into the plasma by the liver, PCSK9 
binds the low-density lipoprotein (LDL) receptor (LDLR) at the surface of hepatocytes. 
This binding prevents LDLR recycling and enhances its degradation in endosomes and 
lysosomes, which results in reduced LDL-cholesterol clearance (12). The recent Glavov 
(13) and Fourier (14) studies have demonstrated that PCSK9 inhibition with monoclonal 
antibodies could reduce the atherosclerosis disease burden and cardiovascular events. 
The potential of PCSK9 as a biotarget in HF is unknown. Herein, we 
hypothesized that, similar to what was shown in patients with coronary artery disease, 
elevated levels of PCSK9 in HF are associated with outcomes. Accordingly, we aimed 
to decipher the value of the PCSK9-LDLR axis for predicting risk in patients with HF in 
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the multicenter BIOlogy Study to TAilored Treatment in Chronic Heart Failure 
(BIOSTAT-CHF) cohort (15).  
 
METHODS 
BIOSTAT-CHF Cohort  
The BIOSTAT-CHF was a multicenter, multinational, prospective, observational study 
that included 2516 patients with worsening signs and/or symptoms of HF from 69 
centers in 11 European countries. The recruitment period was 24 months, from 
December 2010 to December 2012 (15). The median follow-up was 21months 
[interquartile range (IQR) 15–27months]. The Ethics Committees of participating 
institutions approved this study, and all patients provided written consent to participate 
in the study. 
Eligible patients, exclusion criteria, and characteristics of the BIOSTAT-CHF 
cohort have been described elsewhere (15). In brief, the majority of patients were 
hospitalized for acute HF, and the remainder presented with worsening signs and/or 
symptoms of HF at outpatient clinics. Approximately half of the patients were classified 
as New York Heart Association class III. Blood was drawn within days of the 
worsening HF event (either in- or outpatient). 
All deaths and hospitalizations were recorded. The primary outcomes of interest 
were the time to all-cause mortality and the time to a composite of death or unscheduled 
hospitalization for HF. 
PCSK9 and LDL Receptor Assays.  
PCSK9 and LDLR were measured using the Proseek® Multiplex CVDIII panel (Olink 
Proteomics AB, Uppsala, Sweden) according to the manufacturer's instructions. The 
Proximity Extension Assay (PEA) technology used for the Proseek® Multiplex protocol 
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has been well described (16). In brief, pairs of oligonucleotide-labeled antibody probes 
bind to their targeted protein, and if the two probes are brought in close proximity the 
oligonucleotides will hybridize in a pair-wise manner. The addition of a DNA 
polymerase leads to a proximity-dependent DNA polymerization event, generating a 
unique PCR target sequence. The resulting DNA sequence is subsequently detected and 
quantified using a microfluidic real-time PCR instrument (Biomark HD, Fluidigm). 
Data is then quality controlled and normalized using an internal extension control and 
an inter-plate control, to adjust for intra- and inter-run variation. The final assay read-
out is presented in Normalized Protein eXpression (NPX) values, which is an arbitrary 
unit on Log2 scale where a high value corresponds to a higher protein expression. All 
assay validation data (detection limits, intra- and inter-assay precision data, etc) are 
available on manufacturer's website (www.olink.com).  
Statistical analysis 
Continuous variables are expressed as the mean ± standard deviation (SD) or the 
median (IQR) per variable distribution. Discrete variables are presented as percentages. 
Baseline characteristics among PSCK9 and LDLR quartiles were compared with 
ANOVA, Kruskall–Wallis, or chi-squared tests, as appropriate. 
The bivariate correlation of the two exposures was assessed with Spearman's 
rank correlation coefficient. A multivariable linear regression analysis was performed to 
determine the association of LDLR with PCSK9 while adjusting for age, gender, 
ischemic heart disease, LDL-cholesterol, HDL-cholesterol, and eGFR.  
The Cox proportional hazard regression was used to determine the 
simultaneously-adjusted effect of PCSK9 and LDLR on all-cause mortality and on the 
composite of mortality and HF hospitalization. Each of these models included as 
covariates the use of statins and tertiles of the previously derived BIOSTAT risk score 
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(17). Briefly, the BIOSTAT risk score for each endpoint was calculated as the 
probability of achieving the endpoint at a 2-year follow-up. The BIOSTAT risk score 
for mortality included age, blood urea nitrogen, NT-proBNP, serum hemoglobin, and 
the use of a beta-blocker. The BIOSTAT risk score for the composite endpoint included 
age, previous HF-related hospitalization, the presence of edema, systolic blood pressure, 
and the estimated glomerular filtration rate (17). Results are expressed as hazard ratios 
(HR) with their respective 95% CI. The proportionality assumption – tested by means of 
the Schoenfeld residuals - was met for all models. In a sensitivity analysis, LDL 
cholesterol was added as an additional covariate to the previous prognostic models. 
Measures of performance were assessed by means of  C-statistics, integrated 
discrimination improvement (IDI), and net reclassification improvement (NRI)(%). In 
order to match the scope of the BIOSTAT risk score, these indices were calculated at a 
horizon of 2 years. Two variations of the analysis are presented: 1) PCSK9, LDLR, and 
the use of statins are compared over the BIOSTAT risk score alone, and 2) PCSK9 is 
contrasted against LDLR, use of statins, and the BIOSTAT risk score.  
We set a two-sided p-value of <0.05 as the threshold for statistical significance. 
Stata 14.2 (Stata Statistical Software, Release 14 [2015]; StataCorp LP, College Station, 
TX, USA), was used for the main analysis. Risk reclassification analyses were 
implemented in R (Version 3.40; R Foundation for Statistical Computing, Vienna, 
Austria) with the survIDINRI and SurvC1 modules. 
  
RESULTS 
A total of 2174 patients were included in this analysis (Online Figure 1). The mean age 
of the sample was 68 ± 12 years; 581 (49.7%) were female, 1156 (53.2%) had history of 
ischemic heart disease, and 1727 (88.8%) exhibited LVEF ≤40% (4.5% had LVEF in 
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the mid-range and 6.7% had preserved LVEF). The median (IQR) values of PCSK9, 
LDLR, and NT-proBNP were 1.81U/mL (1.45-2.18), 2.98 U/mL (2.45-3.53), and 4148 
pg/mL (2330-8136), respectively. The baseline values of PCSK9 and LDLR across 
quartiles are shown in Tables 1 and 2. Overall, patients in the higher PCSK9 quartiles 
displayed a higher prevalence of ischemic heart disease and prior coronary 
revascularization and higher values of creatinine, and potassium (Table 1). In contrast, 
the disease severity surrogates were inversely related to the LDLR quartiles. Indeed, 
those in the lower LDLR quartiles were older, more frequently males, and exhibited 
higher proportions of prior renal failure and atrial fibrillation. Similarly, the lower 
LDLR quartile displayed lower systolic blood pressure and hemoglobin, and higher 
values of urea and NT-proBNP (Table 2). Regarding medications, higher proportions of 
patients used statins in the upper quartiles of the two studied exposures. (Tables 1, 2). 
LVEF categories, as defined in the ESC Guidelines (1), were similarly distributed 
across PCSK9 and LDLR quartiles (p=0.365 and p=0.193, respectively). 
Circulating PCSK9 predictors  
Online Figure 2 shows the identified predictors of circulating PCSK9 levels. The 
model’s adjusted R-squared was 0.422. A closer look at the positive correlation between 
PCSK9 and LDLR is depicted in Online Figure 3 (r = 0.59; p<0.001). Exploratory 
analyses across NT-proBNP quartiles with PCSK9 and LDLR did not show prognostic 
differences on all-cause mortality or the composite endpoint. 
Mortality endpoint  
During a median follow-up of 1.78 years (IQR: 1.29-2.25), 569 deaths (26.2%) were 
registered. Multivariable analysis that included as covariates the BIOSTAT risk score 
for mortality, LDLR, and statin treatment, revealed a positive linear association between 
PCSK9 and the risk of mortality (p=0.020; Figure 1A). A similar analysis revealed a 
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negative linear association between LDLR and mortality (p=0.025; Figure 1B). The 
estimated HRs from regression modeling are shown in Table 3. Since PCSK9 and 
LDLR levels were highly correlated, we excluded one exposure at a time to assess -on 
the other one- if multicollinearity was artificially changing in the direction of the effect. 
Under this premise, a positive association for all-cause mortality was confirmed for 
PCSK9 and a negative one for LDLR (results not shown). Indeed, both variables’ linear 
trajectories showed opposite directions, with increasing risk at higher PCSK9 levels and 
lower risk at higher LDLR levels (Figure 1). 
In exploratory fashion, several interactions were tested, all with negative results:  
PCSK9 quartiles vs LDLR (p = 0.388); LDLR quartiles vs PCSK9 (p = 0.143); statins 
vs PCSK9 (p = 0.432); statins vs LDLR (p = 0.860); ischemic heart disease vs PCSK9 
(p = 0.271); and ischemic heart disease vs LDLR (p = 0.079). 
The added value in performance for PCSK9, LDLR, and statin treatment over 
the BIOSTAT risk score was confirmed by  C-statistic [0.0120 (0.002-0.022); 
p=0.019], IDI [0.3 (0-1.1)], and NRI [6.0 (0-11.9)]. Similarly, PCSK9 produced a better 
risk reclassification over LDLR, statin treatment, and the BIOSTAT risk score as 
evidenced by IDI [0.6 (0.1-1.8)] and NRI [11.0 (1.0-18.3)].   
Composite endpoint 
At a median follow-up of 1.53 years (IQR, 0.67-2.15), we ascertained 896 (41.2%) 
composite endpoints (composite of death or HF-related hospitalization). In a 
multivariable context, PCSK9 showed a linear and positive association with the risk of 
the combined endpoint (p=0.011; Figure 2A), independent of the effect of  BIOSTAT 
risk score for the composite endpoint, LDLR, and statin treatment; LDLR, however, 
showed a negative but borderline association (p=0.087; Figure 2B). The estimated HRs 
from regression modeling are shown in Table 3. The direction of the effect for both 
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PCSK9 and LDLR were confirmed by excluding one of them at a time to rule-out 
changes due to multicollinearity. 
In exploratory fashion, several interactions were tested, all with negative results:  
PCSK9 quartiles vs LDLR (p = 0.200); LDLR quartiles vs PCSK9 (p = 0.929); statins 
vs PCSK9 (p = 0.485); statins vs LDLR (p = 0.403); ischemic heart disease vs PCSK9 
(p = 0.170); and ischemic heart disease vs LDLR (p = 0.211). 
The added value in performance for PCSK9, LDLR, and statin treatment over 
the BIOSTAT risk score was confirmed by  C-statistic [0.014 (0.006-0.022): p<0.001], 
IDI [0.8 (0.2-1.8)], and NRI [10.8 (2.9-15.0)]. Similarly, PCSK9 produced a better risk 
reclassification over LDLR, statin treatment, and the BIOSTAT risk score both by IDI 
[0.6 (0-1.5)], and NRI [9.8 (0.4-17.7)]. 
Sensitivity analysis 
In a sensitivity analysis, where plasma LDL cholesterol was added as an additional 
covariate, the results were consistent with the main findings, despite a drop in sample 
numbers (n=1000), due to missing LDL cholesterol values. Circulating PCSK9 and 
LDLR levels were independently associated with mortality risk and the composite 
endpoint (Online Table 1). 
 
DISCUSSION 
The present report is the first to show that the PCSK9-LDLR axis was associated with 
poor outcomes in patients with HF. Our sub-analysis of the BIOSTAT-CHF cohort 
indicated that soluble PCSK9 was positively associated with both all-cause mortality 
and the composite endpoint of mortality or HF-related rehospitalizations in patients with 
worsening HF. By contrast, as pathobiologically expected, circulating LDLR was 
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inversely associated with the same two endpoints. Interestingly, the predictive value of 
PCSK9 improved after adjusting for traditional prognosticators and soluble LDLR.  
The predictive value of circulating PCSK9 concentrations was previously 
described in other clinical settings of cardiovascular pathology (19-20). In the context of 
HF, a comprehensive multivariable analysis with validated BIOSTAT risk scores 
showed that higher PCSK9 was associated with an increased incidence of the composite 
endpoint, and this relationship was independent of serum LDL cholesterol, statin use, or 
ischemic HF etiology. Thus, PCSK9 may be considered a risk predictor across the 
cardiovascular disease continuum, from asymptomatic dyslipidemia, through sub-
clinical and clinical atherosclerosis, and in HF, based on our findings (Central 
Illustration).  
 Secreted PCSK9 follows two possible tracks: the first is to bind immediately to 
LDLRs in the liver, and the second is to enter the systemic circulation (12). Once 
bound, the PCSK9/LDLR complex is endocytosed, taken into the lysosomes, and 
undergoes degradation (21). The presence of PCSK9 enhances LDLR degradation; 
therefore this track reduces the LDLR abundance on the cell surface (22). In the plasma, 
circulating PCSK9 can bind to LDLRs on the membranes of various organ systems, 
such as the liver, intestines, kidneys, lungs, pancreas, and adipose tissues (23-27). In the 
present report, although the ability for risk prediction of PCSK9 and LDLR was 
opposite when included in comprehensive multivariable models, their circulating 
concentrations showed a significant positive correlation. This finding may reflect the 
already recognized complexity of the PCSK9-LDLR axis (28). Indeed, Tavori et al 
report that in addition to the straightforward mechanism of action (PCSK9 terminating 
the lifecycle of LDLR), there are more complex interactions between PCSK9, LDLR 
and plasma lipoprotein levels, including: (a) the presence of both parallel and reciprocal 
14 
 
regulation of surface LDLR and plasma PCSK9; (b) a correlation between PCSK9 and 
LDL cholesterol levels dependent not only on the fact that PCSK9 removes hepatic 
LDLR, but also due to the fact that up to 40% of plasma PCSK9 is physically associated 
with LDL; and (c) an association between plasma PCSK9 production and the assembly 
and secretion of triglyceride-rich lipoproteins (28).  
Despite numerous advances in HF treatments, which block both the sympathetic 
nervous system and the renin-angiotensin-aldosterone system, the morbidity and 
mortality of patients with HF remain unacceptably high (29). Our finding that PCSK9 
could predict risk in HF may serve as a basis for designing prospective studies that aim 
to inhibit PCSK9, either with specific PCSK9 neutralizing monoclonal antibodies or 
with the administration of small, interfering RNAs (siRNAs) that specifically bind and 
inhibit translation of PCSK9 mRNAs (13,14,30).  
In patients with acute coronary syndromes, the potential benefit of treatment 
with PCSK9 antibodies may be two-fold, because it could both reduce LDL cholesterol 
and stabilize plaques (10). Indeed, PCSK9 adversely affects coronary plaques through 
several pathways, including proinflammatory LDL oxidation and direct modification of 
plaque composition. Moreover, PCSK9 is associated with the inflammatory response, 
which is largely based on NF-κB–mediated expression of proinflammatory genes, 
including cytokines, chemokines, and adhesion molecules (31,32). The PCSK9-induced 
NF-κB pathway can upregulate tissue factor expression, which enhances the thrombotic 
substrate in atherosclerotic plaques (33). In the context of HF, it is reasonable to 
speculate that plaque stabilization, combined with reductions in the prothrombotic and 
proinflammatory states, accomplished by inhibiting PCSK9, might represent a new 
avenue of treatment for preventing disease progression, when the current optimal 
medical treatment is insufficient. It is unclear whether this strategy will be useful across 
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all HF etiologies, or only for those of ischemic origin; this issue should be investigated 
in future, well-designed, prospective clinical trials.  
Two randomized clinical trials that explored reducing cholesterol levels with 
rosuvastatin in patients with HF did not demonstrate a clear benefit (7,8). Rosuvastatin 
is a hydrophilic statin, which relies on active transport into hepatocytes to exert its 
effect and has poor penetration into extrahepatic tissues; thus, it has less risk of adverse 
effects but also very low uptake by cardiac muscle. No randomized studies have been 
performed with lipophilic statins (simvastatin, atorvastatin), which tend to achieve 
higher levels of exposure in nonhepatic tissues, have very high cardiac muscle uptake, 
and in real-life scenarios have shown some benefit (9,34). Current guidelines do not 
recommend the use of statins in patients with HF (1). Whether interfering with 
cholesterol-related mechanistic pathway may be beneficial in selected patients with HF 
is not a totally settled issue (35). 
Limitations: The current study had some limitations. First, the data presented here are 
valid for patients with worsening HF, mainly due to reduced LVEF. It remains to be 
determined whether soluble PCSK9 is also a good predictor for patients with stable 
chronic HF. Currently available data in the context of coronary artery disease showed in 
mice that plasma PCSK9 concentration was mostly elevated in the early hours after an 
acute coronary syndrome (36). The second limitation was that the assay used to measure 
PCSK9 and LDLR was designed for research only, and its use cannot be recommended 
in clinical practice. Nevertheless, both exposures were measured with state-of-the art 
proteomics technology, currently available and well validated (16). The last limitation 
was that genetic mutations that might determine PCSK9 levels were not measured in 
patients enrolled in the BIOSTAT-CHF trial. PCSK9 gain-of-function mutations have 
been associated with increased severity in coronary atherosclerosis (37). 
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CONCLUSION 
The PCSK9-LDLR axis has been investigated expeditiously, from discovery to targeted 
therapy, in dyslipidemia and coronary atherosclerosis. Here, we provided the first 
evidence of PCSK9 participation in HF. Indeed, HF risk was positively associated with 
circulating PCSK9 and negatively associated with LDLR in patients with worsening 
HF. Future studies are needed to better understand the PCSK9-LDLR axis in HF, and to 
assess whether PCSK9 inhibition or silencing might lead to better outcomes in HF. 
 
PERSPECTIVES  
Competency in Medical Knowledge: Proprotein convertase subtilisin/kexin type 9 
(PCSK9), which binds the low-density lipoprotein receptor (LDLR) and prevents its 
recycling, is a risk predictor and biotarget in atherosclerosis progression. Here, we 
demonstrated that HF risk was positively associated with circulating PCSK9 and 
negatively associated with LDLR levels. 
 
Translational Outlook: Our data provided a basis for future research to investigate 
whether HF outcomes might be improved by inhibiting PCSK9, either with specific 
PCSK9-neutralizing monoclonal antibodies or with small interfering RNAs (siRNAs). 
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FIGURE LEGENDS 
Figure 1: Multivariable analyses for all-cause mortality. (A) HR-gradient, with the 
median PCSK9 value (1.81 U/mL) as reference. Analysis adjusted for 
LDLR, statins, and the BIOSTAT risk score for mortality. (B) HR-
gradient, with the median LDLR value (2.98 U/mL) as reference. 
Analysis adjusted for PCSK9, statins, and the BIOSTAT risk score for 
mortality. HR, hazard ratio; PCSK9, proprotein convertase 
subtilisin/kexin type 9; LDLR, low density lipoprotein- receptor. U/mL, 
is a Normalized Protein eXpression (NPX) arbitrary unit (see Methods 
for details).  
Figure 2: Multivariable analyses for the composite endpoint (mortality or HF-
related hospitalization). (A) HR-gradient, with the median PCSK9 value 
(1.81 U/mL) as reference. Analysis adjusted for LDLR, statins, and the 
BIOSTAT risk score for the composite endpoint. (B) HR-gradient, with 
the median LDLR value (2.98 U/mL) as reference. Analysis adjusted for 
PCSK9, statins, and the BIOSTAT risk score for the composite endpoint. 
HR, hazard ratio; PCSK9, proprotein convertase subtilisin/kexin type 9; 
LDLR, low density lipoprotein-receptor. U/mL, is a Normalized Protein 
eXpression (NPX) arbitrary unit (see Methods for details). 
 
Central Illustration: PCSK9 across the cardiovascular continuum. In heart failure we 
proved evidence of elevated PCSK9 levels, which were associated 
with poor outcomes. There is no evidence of PCSK9 inhibition in 
HF. 
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Table 1: Demographic, clinical, laboratory and treatment characteristics relative to PCSK9 quartiles 
Variables 
PCSK9 
P value 
 
1st Quartile 
N= 544 
2nd Quartile 
N=543 
3rd Quartile 
N=544 
4th Quartile 
N=543 
Age, years, mean (sd)                                         69 (12) 69 (13) 67 (12) 68 (12) 0.08 
Sex, male, n (%)                                                 413 (75.9) 401 (73.8) 391 (71.9) 388 (71.5) 0.32 
Ischemic heart disease, n (%)                     273 (50.7) 273 (51.3) 277 (52.7) 333 (61.8) 0.001 
Dilated cardiomypathy, n (%)             167 (30.7) 186 (34.3) 157 (28.9) 156 (28.7) 0.17 
Hypertension, n (%)                                     347 (63.8) 322 (59.3) 323 (59.4) 355 (65.4) 0.09 
Diabetes mellitus, n (%)                                         173 (31.8) 172 (31.7) 171 (31.4) 185 (34.1) 0.77 
Renal failure, n (%)                                    162 (29.8) 153 (28.2) 131 (24.1) 169 (31.1) 0.06 
Atrial fibrillation, n (%)                              243 (44.7) 266 (49.0) 254 (46.7) 228 (42.0) 0.12 
Heart rate (bpm), mean (SD)                     81 (19) 80 (20) 79 (20) 80 (19) 0.67 
LVEF %, mean (SD)* 32 (11) 30 (10) 31 (10) 31 (11) 0.28 
Laboratory                                           
   Hemoglobin (g/dL), mean (SD)                     13.0 (1.9) 13.1 (1.8) 13.2 (1.9) 13.4 (2.0) 0.07 
   Serum creatinine, mg/dl, mean (SD)                            1.28 (0.52) 1.27 (0.53) 1.27 (0.67) 1.38 (0.74) 0.008 
   NT-proBNP (ng/L), median (IQR)                  3975 (2288; 7751) 4654 (2364; 8475) 3784 (2242; 8105) 3949 (2360; 8000) 0.61 
   LDLc (mmol/L), mean (SD) ¶                          2.54 (0.99) 2.50 (0.98) 2.65 (1.11) 2.67 (1.14) 0.21 
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Treatment                                             
   Diuretics, n (%)                           543 (99.8) 543 (100.0) 544 (100.0) 542 (99.8) 0.57 
   MRA, n (%)               270 (49.6) 290 (53.4) 300 (55.1) 282 (51.9) 0.31 
   Betablocker, n (%)                           454 (83.5) 451 (83.1) 443 (81.4) 459 (84.5) 0.59 
   ACEI/ARB, n (%)                               390 (71.7) 387 (71.3) 383 (70.4) 399 (73.5) 0.72 
   Statins, n (%)                               257 ( 47.3) 251 (46.1) 301 (55.3) 340 (62.2) <0.001 
 
 
PCSK9, proprotein convertase subtilisin/kexin type 9; LDLR, low density lipoprotein receptor; LDLc, LDL cholesterol; NTpro-BNP, N-terminus 
pro B-type natriuretic peptide; MRA, mineralo-receptor antagonists; ACEI, angiotensin coverting-enzyme inhibitors; ARB, angiotensin receptor 
2 inhibitors; SD, standard deviation; IQR, interquartile range; bpm, beats per minute. U/mL, is a Normalized Protein eXpression (NPX) arbitrary 
unit (see Methods forr details). *data available in 1946 patients; ¶data available in 1000 patients. 
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Table 2: Demographic, clinical, laboratory and treatment characteristics relative to LDLR quartiles 
Variables 
LDLR 
P value 
 
1st Quartile 
N= 544 
2nd Quartile 
N=543 
3rd Quartile 
N=544 
4th Quartile 
N=543 
Age, years, mean (sd)                                         70 (12) 69 (12) 68 (12) 66 (12) < 0.001 
Sex, male, n (%)                                                 425 (78.1) 409 (75.3) 397 (73.0) 362 (66.7) < 0.001 
Ischemic heart disease, n (%)                     280 (52.3) 295 (55.5) 288 (54.0) 293 (54.8) 0.76 
Dilated cardiomypathy, n (%)             154 (28.3) 161 (29.7) 163 (30.0) 188 (34.6) 0.12 
Hypertension, n (%)                                     349 (64.2) 314 (57.8) 327 (60.1) 357 (65.7) 0.03 
Diabetes mellitus, n (%)                                         167 (30.7) 162 (29.8) 177 (32.5) 195 (35.9) 0.15 
Renal failure, n (%)                                    180 (33.1) 153 (28.2) 136 (25.0) 146 (26.9) 0.02 
Atrial fibrillation, n (%)                              285 (52.4) 259 (47.7) 250 (46.0) 197 (36.3) < 0.001 
Heart rate (bpm), mean (SD)                     80 (19) 80 (20) 81 (21) 80 (19) 0.94 
LVEF %, mean (SD)* 31 (11) 30 (11) 31 (11) 31 (10) 0.50 
Laboratory                                           
   Hemoglobin (g/dL), mean (SD)                     12.8 (1.9) 13.2 (1.9) 13.2 (1.9) 13.5 (1.9) < 0.001 
   Serum creatinine, mg/dl, mean (SD)                            1.32 (0.59) 1.28 (0.71) 1.31 (0.60) 1.29 (0.58) 0.66 
   NT-proBNP (ng/L), median (IQR)                  4339 (2420; 8068) 5302 (2767; 9449) 3632 (2358; 7340) 3499 (1775; 7337) < 0.001 
Treatment                                             
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   Diuretics, n (%)                           543 (99.8) 543 (100.0) 544 (100.0) 542 (99.8) 0.57 
   MRA, n (%)               297 (54.6) 299 (55.1) 277 (50.9) 269 (49.5) 0.18 
   Betablocker, n (%)                           440 (80.9) 462 (85.1) 448 (82.4) 457 (84.2) 0.25 
   ACEI/ARB, n (%)                               396 (72.8) 383 (70.5) 382 (70.2) 398 (73.3) 0.58 
   Statins, n (%)                               268 (49.9) 279 (51.3) 278 (51.1) 324 (59.7) 0.003 
 
LDLR, low density lipoprotein receptor; PCSK9, proprotein convertase subtilisin/kexin type 9; LDLc, LDL cholesterol; NTpro-BNP, N-terminus 
pro B-type natriuretic peptide; MRA, mineralo-receptor antagonists; ACEI, angiotensin coverting-enzyme inhibitors; ARB, angiotensin receptor 
2 inhibitors; SD, standard deviation; IQR, interquartile range; LVEF, left ventricular ejection fraction; bpm, beats per minute. U/mL, is a 
Normalized Protein eXpression (NPX) arbitrary unit (see Methods for details). *data available in 1946 patients; ¶data available in 1000 patients 
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Table 3. Regression modeling for all-cause mortality and the composite endpoint of 
mortality and/or HF-related hospitalization 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
PCSK9, proprotein convertase subtilisin/kexin type 9; LDLR, low density lipoprotein- receptor; 
HR, hazard ratio; CI, confidence interval.†BIOSTAT Score for mortality includes: age, blood 
urea nitrogen, NT-pro-BNP, serum hemoglobin, and use of beta-blocker; ‡BIOSTAT Score for 
mortality/HF-related rehospitalization includes: age, previous HF-related hospitalization, 
presence of edema, systolic blood pressure, and estimated glomerular filtration rate. *Omnibus P 
value. 
Endpoint HR 95% CI P-value 
All-cause mortality 
PCSK9 1.24 1.04 - 1.49 0.020 
LDLR 0.86 0.76 - 0.98 0.025 
Statins 1.03 0.87 - 1.22 0.725 
Risk score†   <0.001* 
     Tertile 1 1.00   
     Tertile 2 2.35 1.76 - 3.13 0.000 
     Tertile 3 6.41 4.92 - 8.36 0.000 
Mortality/HF-related hospitalization 
PCSK9 1.21 1.05 - 1.40 0.011 
LDLR 0.92 0.83 - 1.01 0.087 
Statins 1.25 1.09 - 1.42 0.001 
Risk score‡   <0.001* 
     Tertile 1 1.00   
     Tertile 2 2.87 2.32 - 3.56 0.000 
     Tertile 3 6.13 5.00 - 7.52 0.000 
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